Rapport Therapeutics (NASDAQ:RAPP - Get Free Report) shares gapped up prior to trading on Friday . The stock had previously closed at $24.53, but opened at $25.62. Rapport Therapeutics shares last traded at $25.02, with a volume of 2,436 shares.
Rapport Therapeutics Trading Up 0.4 %
The company's 50 day simple moving average is $21.85.
Rapport Therapeutics (NASDAQ:RAPP - Get Free Report) last posted its quarterly earnings results on Thursday, August 8th. The company reported ($1.70) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.68) by ($1.02). On average, analysts predict that Rapport Therapeutics will post -3.46 earnings per share for the current year.
Hedge Funds Weigh In On Rapport Therapeutics
Several hedge funds have recently made changes to their positions in RAPP. Perceptive Advisors LLC purchased a new stake in Rapport Therapeutics in the second quarter worth about $17,403,000. Millennium Management LLC purchased a new position in shares of Rapport Therapeutics in the 2nd quarter valued at approximately $2,716,000. ARCH Venture Management LLC bought a new stake in shares of Rapport Therapeutics during the second quarter valued at approximately $86,730,000. TD Asset Management Inc purchased a new stake in Rapport Therapeutics in the second quarter worth $2,361,000. Finally, Johnson & Johnson bought a new position in Rapport Therapeutics in the second quarter worth $58,105,000.
Rapport Therapeutics Company Profile
(
Get Free Report)
Rapport Therapeutics Inc is a clinical-stage biotechnology company. It focused on discovery and development of transformational small molecule medicines for patients suffering from central nervous system disorders. Rapport Therapeutics Inc is based in BOSTON.
Recommended Stories
Before you consider Rapport Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Rapport Therapeutics wasn't on the list.
While Rapport Therapeutics currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio? Find out by clicking the link below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
